INDSWFTLAB

Ind-Swift Laboratories Ltd, incorporated in 1995 and headquartered in Chandigarh, operates in the pharmaceutical and bulk drugs industries. The company specializes in pharmaceutical formulations, having exited its Active Pharmaceutical Ingredients (API) and Contract Research and Manufacturing Services (CRAMS) businesses by selling its API division to PI Industries in March 2024. Historically, Ind-Swift was recognized for its leadership in the Macrolide Antibiotic sector. In July 2025, the company concluded a merger with Ind-Swift Limited. Currently, it functions as a debt-free entity focusing exclusively on the global formulations market.